Rankings
▼
Calendar
VRDN FY 2012 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
VRDN
Viridian Therapeutics, Inc.
$2B
FY 2012 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$4M
Gross Profit
$1M
31.0% margin
Operating Income
-$4M
-91.4% margin
Net Income
-$7M
-163.7% margin
EPS (Diluted)
$-38.75
Cash Flow
Operating Cash Flow
-$6M
Free Cash Flow
-$6M
Stock-Based Comp.
$7,955
Balance Sheet
Total Assets
$3M
Total Liabilities
$24M
Stockholders' Equity
-$21M
Cash & Equivalents
$112,534
← FY 2013
All Quarters
